POMPANO BEACH, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. BSEM, a number one MedTech firm targeted on the event, manufacturing, and commercialization of placental-derived merchandise for superior wound care, pronounces that Jason Matuszewski, the Firm’s Chief Govt Officer, will current a company overview and replace on the Biotech Showcase 2025 convention, which is happening in San Francisco, CA January 13-15, 2025. BioStem’s senior administration will even host one-on-one conferences in the course of the convention.
Biotech Showcase 2025 Presentation Particulars:
Date: Monday, January 13, 2025
Time: 2:30 PM PT
Monitor: Yosemite-C
Webcast Hyperlink: HERE
Webcast Archive: HERE
Request a Assembly with Administration:
To schedule a one-on-one assembly on the Biotech Showcase convention or in San Francisco January 13-15, please e mail [email protected].
About Biotech Showcase:
Biotech Showcase is an investor and networking convention dedicated to offering non-public and public biotechnology and life sciences firms with a possibility to current to, and meet with, buyers and pharmaceutical executives in a single place. Traders and biopharmaceutical executives from all over the world collect at Biotech Showcase throughout this bellwether week which units the tone for the approaching 12 months. Now in its seventeenth 12 months, this well-established, extremely revered convention options a number of tracks of presenting firms, plenary periods, workshops, networking, and a possibility to schedule one-to-one conferences.
About BioStem Applied sciences, Inc. BSEM:
BioStem Applied sciences is a number one innovator targeted on harnessing the pure properties of perinatal tissue within the improvement, manufacture, and commercialization of allografts. The Firm is targeted on manufacturing merchandise that change lives, leveraging its proprietary BioREtain® processing methodology. BioREtain® has been developed by making use of the newest analysis in superior wound care, targeted on sustaining progress components and preserving tissue construction. BioStem Applied sciences’ high quality administration system and customary working procedures have been reviewed and accredited by the American Affiliation of Tissue Banks (“AATB”). These techniques and procedures are established per present Good Tissue Practices (“cGTP”) and present Good Manufacturing Processes (“cGMP”). Our portfolio of high quality manufacturers contains AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Every BioStem Applied sciences placental allograft is processed on the Firm’s FDA registered and AATB accredited web site in Pompano Seashore, Florida.
For extra data go to biostemtechnologies.com and comply with us on Twitter and LinkedIn.
Be part of BioStem’s Distribution Record & Social Media:
To comply with the newest developments at BioStem, sign-up to the Firm’s e mail distribution record HERE, and comply with us on Twitter and LinkedIn.
Ahead-Wanting Statements:
Apart from statements of historic reality, this launch additionally accommodates forward-looking statements throughout the that means of the Non-public Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future occasions. Ahead-looking statements could also be recognized utilizing phrases equivalent to “forecast,” “intend,” “search,” “goal,” “anticipate,” “imagine,” “anticipate,” “estimate,” “plan,” “outlook,” and “venture” and different comparable expressions that predict or point out future occasions or traits or that aren’t statements of historic issues. Ahead-looking statements with respect to the operations of the Firm, methods, prospects and different features of the enterprise of the Firm are primarily based on present expectations which might be topic to identified and unknown dangers and uncertainties, which might trigger precise outcomes or outcomes to vary materially from expectations expressed or implied by such forward-looking statements. These components embrace, however aren’t restricted to: (1) the influence of any modifications to the reimbursement ranges for the Firm’s merchandise; (2) the Firm faces important and persevering with competitors, which might adversely have an effect on its enterprise, outcomes of operations and monetary situation; (3) fast technological change might trigger the Firm’s merchandise to turn into out of date and if the Firm doesn’t improve its product choices by its analysis and improvement efforts, it might be unable to successfully compete; (4) to be commercially profitable, the Firm should persuade physicians that its merchandise are protected and efficient alternate options to present remedies and that its merchandise must be used of their procedures; (5) the Firm’s capacity to boost funds to develop its enterprise; (6) the Firm has incurred important losses since inception and should incur losses sooner or later; (7) modifications in relevant legal guidelines or laws; (8) the likelihood that the Firm could also be adversely affected by different financial, enterprise, and/or aggressive components; (9) the Firm’s capacity to keep up manufacturing of its merchandise in enough portions to fulfill demand; and (10) the COVID-19 pandemic and its influence, if any, on the Firm’s fiscal situation and outcomes of operations; You might be cautioned to not place undue reliance upon any forward-looking statements, which communicate solely as of the date made. Though it might voluntarily achieve this now and again, the Firm undertakes no dedication to replace or revise the forward-looking statements, whether or not because of new data, future occasions or in any other case, besides as required by relevant securities legal guidelines.
BioStem Applied sciences, Inc.:
Telephone: 954-380-8342
Web site: http://www.biostemtechnologies.com
E-Mail: [email protected]
Twitter: @BSEM_Tech
Fb: BioStemTechnologies
LinkedIn: BioStem Technologies LinkedIn
PCG Advisory
Jeff Ramson
[email protected]
646-863-6893
Market Information and Knowledge dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
